Compare AbbVie Inc (ABBV) vs Aon PLC (AON) Price & Performance

AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.

The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.

AON trades at $359.82, up 0.66% with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a 22.54% net income margin and 46.82% ROE, supported by revenue growth to $17.18B in 2025. Analyst consensus is a Buy with a $385.50 price target, and the company continues to innovate with initiatives like the Aon DPX platform launch in 2026.

Outlook remains positive driven by AI integration and strategic growth, though risks include debt levels and market volatility. The stock offers upside potential near consensus targets, but investors should monitor execution of the 3x3 plan and competitive pressures in the insurance brokerage sector.